Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.

doi:10.1684/ecn.2019.0438

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.

European cytokine network - 1 Dec 2019

Chatrabnous Nazanin, Jafarzadeh Abdollah, Ghaderi Abass, Ariafar Ali, Aminizadeh Najmeh, Ghassabi Farzaneh, Nemati Maryam

Abstract excerpt

BACKGROUND: Inflammation has a prominent role in cancer development and interleukin (IL)-33 has both inflammatory and anti-inflammatory properties. The aim of this study was to measure IL-33 quantities and genetic alterations in the rs1929992 SNP within IL-33 gene in patients with prostate cancer (PC). METHODS: This investigation was conducted on blood specimens from 150 newly diagnosed PC patients and 150...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Interleukin-33

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Odds Ratio

Share to Prostatic Neoplasms

Share to Risk

Source

Open in PubMed

Identifiers

PMID: 32096476
DOI: 10.1684/ecn.2019.0438

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of elevated interleukin-33 serum levels with tumorstages in patients with prostate cancer.PMID 32096476Read ↗

Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer.Semantic proximity Read ↗

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.Semantic proximity Read ↗

Interleukin-6 polymorphism and prostate cancer risk in population of Eastern Croatia.Semantic proximity Read ↗

Interleukin-6 promoter variants, prostate cancer risk, and survival.Semantic proximity Read ↗

Association of IL-1β Gene Polymorphism with Prostate Cancer Severity, Prostate Volume, and PSA Levels: A Case-Control Study.Semantic proximity Read ↗

Association between interleuleukin-1β polymorphism (rs16944) and biomarkers levels in Iraqi patients with prostate cancer.Semantic proximity Read ↗

Interleukin-6 gene -174G>C and -636G>C promoter polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Interleukins-6 -174G/C (rs1800795) and -572C/G (rs1800796) polymorphisms and prostate cancer risk.Semantic proximity Read ↗

Association between IL-1 β polymorphism (rs16944) and Biomarkers levels in Iraqi patients with prostate cancerSemantic proximity Read ↗

IL-10 polymorphisms and prostate cancer risk: a meta-analysis.Semantic proximity Read ↗

Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.Semantic proximity Read ↗

The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.